title: Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention.
abstract: OBJECTIVE
  Nicorandil, an opener of ATP-sensitive K+ channels, was used to treat angina in patients with coronary artery disease. In this study, we aim to investigate the cardioprotective effects of single oral dose of nicorandil in patients undergoing selective percutaneous coronary intervention (PCI).
  
  
  METHODS
  One hundred and thirty-eight patients with acute coronary syndrome undergoing PCI from July 2011 to October 2012 were randomly divided into control group (group 1, n = 47), 10 mg oral nicorandil group (group 2, n = 45), and 20 mg oral nicorandil group (group 3, n = 46) about 2 hours before procedure, respectively. Cardiac troponin I (cTnI) levels were determined at 20 ~ 24 hours after PCI.
  
  
  RESULTS
  There was a significant difference in the rate of any cTnI elevation among the three groups (group 1: 36.17%, group 2: 20.00%, group 3: 15.22%, p = 0.0176). With respect to the frequency of cTnI elevation ≥ 3 and 5 × the upper limit of normal (ULN), there also had statistical difference among the three groups (17.02% in group 1, 8.89% in group 2, and 4.35% in group 3, respectively for cTnI elevation ≥ 3 × ULN, p = 0.0428; 12.77% in group 1, 6.67% in group 2, and 2.17% in group 3, respectively, for cTnI elevation ≥ 5 × ULN, p = 0.0487). Logistic regression analysis showed that LVEF (OR = 0.915, 95% CI = 0.853-0.981) and the use of nicorandil (OR = 0.516, 95% CI = 0.267-0.996) before PCI were independent protective factors of myocardial injury.
  
  
  CONCLUSIONS
  Single oral dose of nicorandil (10 mg, 20 mg) 2 hours before the PCI procedure could decrease the incidence of peri-procedure myocardial injury and PCI-related myocardial infarction.
authors.affiliation: Department of Cardiology, the Second Hospital of Hebei Medical University; Shijiazhuang City P.R.-China. cuiwei@medmail.com.cn.
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.forename: Jidong
authors.initials: J
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Cui
authors.forename: Fan
authors.initials: F
authors.lastname: Liu
authors.forename: Ruiqin
authors.initials: R
authors.lastname: Xie
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Yang
authors.forename: Guoqiang
authors.initials: G
authors.lastname: Gu
authors.forename: Hongmei
authors.initials: H
authors.lastname: Zheng
authors.forename: Jingchao
authors.initials: J
authors.lastname: Lu
authors.forename: Xiuchun
authors.initials: X
authors.lastname: Yang
authors.forename: Guangming
authors.initials: G
authors.lastname: Zhang
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Xue
authors.initials: X
authors.lastname: Geng
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000628:therapy*; D000284:Administration, Oral; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020108:Nicorandil / Q000008:administration & dosage*; D062645:Percutaneous Coronary Intervention; D011184:Postoperative Period; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D002316:Cardiotonic Agents; D014665:Vasodilator Agents; D020108:Nicorandil